Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat

D. Reglodi, Aniko Somogyvari-Vigh, Sandor Vigh, Tamas Kozicz, Akira Arimura

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Background and Purpose - Many substances have been shown to reduce brain damage in models of stroke, but mainly when given either before or shortly after the onset of ischemia. Delayed systemic administration of pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to attenuate the neuronal damage in the hippocampus in a model of global ischemia in rats. The present study examined the neuroprotective action of delayed systemic administration of PACAP38 in a model of transient focal ischemia produced by middle cerebral artery occlusion (MCAO) in rats. Methods - We administered PACAP38 as an intravenous bolus (20 nmol/kg body wt) followed by an intravenous infusion for 48 hours using a micro-osmotic pump at a rate of 160 pmol/μL per hour, beginning 4, 8, or 12 hours after a 2-hour transient MCAO using a filament model. The size of the infarct was determined by examining 2-mm-thick brain sections stained with triphenyltetrazolium chloride, followed by image analysis. Control animals received intravenously 0.1% bovine serum albumin in 0.9% saline as a bolus and infusion at the same time intervals. Results - The administration of PACAP38 beginning 4 hours after MCAO significantly reduced the infarct size by 50.88%. Treatment with PACAP38 starting 8 or 12 hours after the onset of ischemia did not result in a significant reduction of the infarct size, although infarct volumes tended to be smaller than in the control groups. Conclusions - Systemic administration of PACAP38 should be clinically useful for reducing brain damage resulting from stroke even when administration is delayed for several hours.

Original languageEnglish
Pages (from-to)1411-1417
Number of pages7
JournalStroke
Volume31
Issue number6
Publication statusPublished - Jun 2000

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Middle Cerebral Artery Infarction
Ischemia
Brain
Stroke
Bovine Serum Albumin
Intravenous Infusions
Hippocampus
Control Groups

Keywords

  • Cerebral infarction
  • Middle cerebral artery occlusion
  • Neuropeptides
  • Neuroprotection
  • Rats

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. / Reglodi, D.; Somogyvari-Vigh, Aniko; Vigh, Sandor; Kozicz, Tamas; Arimura, Akira.

In: Stroke, Vol. 31, No. 6, 06.2000, p. 1411-1417.

Research output: Contribution to journalArticle

Reglodi, D, Somogyvari-Vigh, A, Vigh, S, Kozicz, T & Arimura, A 2000, 'Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat', Stroke, vol. 31, no. 6, pp. 1411-1417.
Reglodi, D. ; Somogyvari-Vigh, Aniko ; Vigh, Sandor ; Kozicz, Tamas ; Arimura, Akira. / Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. In: Stroke. 2000 ; Vol. 31, No. 6. pp. 1411-1417.
@article{1c715a9cd2614ffaa7d0b564db73769e,
title = "Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat",
abstract = "Background and Purpose - Many substances have been shown to reduce brain damage in models of stroke, but mainly when given either before or shortly after the onset of ischemia. Delayed systemic administration of pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to attenuate the neuronal damage in the hippocampus in a model of global ischemia in rats. The present study examined the neuroprotective action of delayed systemic administration of PACAP38 in a model of transient focal ischemia produced by middle cerebral artery occlusion (MCAO) in rats. Methods - We administered PACAP38 as an intravenous bolus (20 nmol/kg body wt) followed by an intravenous infusion for 48 hours using a micro-osmotic pump at a rate of 160 pmol/μL per hour, beginning 4, 8, or 12 hours after a 2-hour transient MCAO using a filament model. The size of the infarct was determined by examining 2-mm-thick brain sections stained with triphenyltetrazolium chloride, followed by image analysis. Control animals received intravenously 0.1{\%} bovine serum albumin in 0.9{\%} saline as a bolus and infusion at the same time intervals. Results - The administration of PACAP38 beginning 4 hours after MCAO significantly reduced the infarct size by 50.88{\%}. Treatment with PACAP38 starting 8 or 12 hours after the onset of ischemia did not result in a significant reduction of the infarct size, although infarct volumes tended to be smaller than in the control groups. Conclusions - Systemic administration of PACAP38 should be clinically useful for reducing brain damage resulting from stroke even when administration is delayed for several hours.",
keywords = "Cerebral infarction, Middle cerebral artery occlusion, Neuropeptides, Neuroprotection, Rats",
author = "D. Reglodi and Aniko Somogyvari-Vigh and Sandor Vigh and Tamas Kozicz and Akira Arimura",
year = "2000",
month = "6",
language = "English",
volume = "31",
pages = "1411--1417",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat

AU - Reglodi, D.

AU - Somogyvari-Vigh, Aniko

AU - Vigh, Sandor

AU - Kozicz, Tamas

AU - Arimura, Akira

PY - 2000/6

Y1 - 2000/6

N2 - Background and Purpose - Many substances have been shown to reduce brain damage in models of stroke, but mainly when given either before or shortly after the onset of ischemia. Delayed systemic administration of pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to attenuate the neuronal damage in the hippocampus in a model of global ischemia in rats. The present study examined the neuroprotective action of delayed systemic administration of PACAP38 in a model of transient focal ischemia produced by middle cerebral artery occlusion (MCAO) in rats. Methods - We administered PACAP38 as an intravenous bolus (20 nmol/kg body wt) followed by an intravenous infusion for 48 hours using a micro-osmotic pump at a rate of 160 pmol/μL per hour, beginning 4, 8, or 12 hours after a 2-hour transient MCAO using a filament model. The size of the infarct was determined by examining 2-mm-thick brain sections stained with triphenyltetrazolium chloride, followed by image analysis. Control animals received intravenously 0.1% bovine serum albumin in 0.9% saline as a bolus and infusion at the same time intervals. Results - The administration of PACAP38 beginning 4 hours after MCAO significantly reduced the infarct size by 50.88%. Treatment with PACAP38 starting 8 or 12 hours after the onset of ischemia did not result in a significant reduction of the infarct size, although infarct volumes tended to be smaller than in the control groups. Conclusions - Systemic administration of PACAP38 should be clinically useful for reducing brain damage resulting from stroke even when administration is delayed for several hours.

AB - Background and Purpose - Many substances have been shown to reduce brain damage in models of stroke, but mainly when given either before or shortly after the onset of ischemia. Delayed systemic administration of pituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to attenuate the neuronal damage in the hippocampus in a model of global ischemia in rats. The present study examined the neuroprotective action of delayed systemic administration of PACAP38 in a model of transient focal ischemia produced by middle cerebral artery occlusion (MCAO) in rats. Methods - We administered PACAP38 as an intravenous bolus (20 nmol/kg body wt) followed by an intravenous infusion for 48 hours using a micro-osmotic pump at a rate of 160 pmol/μL per hour, beginning 4, 8, or 12 hours after a 2-hour transient MCAO using a filament model. The size of the infarct was determined by examining 2-mm-thick brain sections stained with triphenyltetrazolium chloride, followed by image analysis. Control animals received intravenously 0.1% bovine serum albumin in 0.9% saline as a bolus and infusion at the same time intervals. Results - The administration of PACAP38 beginning 4 hours after MCAO significantly reduced the infarct size by 50.88%. Treatment with PACAP38 starting 8 or 12 hours after the onset of ischemia did not result in a significant reduction of the infarct size, although infarct volumes tended to be smaller than in the control groups. Conclusions - Systemic administration of PACAP38 should be clinically useful for reducing brain damage resulting from stroke even when administration is delayed for several hours.

KW - Cerebral infarction

KW - Middle cerebral artery occlusion

KW - Neuropeptides

KW - Neuroprotection

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=0034035403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034035403&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 1411

EP - 1417

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -